Collection / CJC-1295 without DAC + Ipamorelin 20 mg
CJC-1295 without DAC + Ipamorelin 20 mg
This premixed material combines CJC-1295 without DAC and ipamorelin for growth-axis research. The component roles span GHRH and ghrelin-receptor signalling; the listed strength is the complete blend total.
Simulation only · No real order or payment.
CJC-1295 + Ipamorelin blend
Also known as: CJC / IPA
Blend evidence review pendingResearch & handling
Not for human or veterinary use. Storage, handling, identity and purity require verified batch documentation. No dosing or treatment advice is provided.
At a glance
Non-DAC CJC component
The listed non-DAC analogue belongs to the GHRH pathway; prolonged DAC trial findings do not apply.
Ipamorelin component
Ipamorelin brings a separate ghrelin-receptor secretagogue identity.
Combined formulation
Component proportions require documentation. Individual component studies do not test this finished blend.
Explore the study context and sources below. For laboratory research only.
Studies & context
This blend names CJC-1295 and ipamorelin. Long-acting CJC-1295 trial data cannot be assigned to a non-DAC or unspecified CJC component, or to the combination.
Blend evidence review pendingComponent studies do not establish this blend’s effects. Ratios and exact identities require documentation.
Published research is separate from PEPTIVIA identity, content, purity, sterility and batch documentation. No source-supplier report verifies PEPTIVIA material.